CLAIMS

1. Use of B-cell activating factor ~~for manufacturing a preparation~~in the manufacture of a medicament for the treatment of ~~for increasing~~low mucosal immunity of infants or sucklings.

~~2. A preparation for peroral administration, destined for stimulation of mucosal immunity of infants or sucklings, characterized in that it contains B-cell activating factor.~~

~~3~~2. ~~The~~ A preparation ~~according to claim 2~~for peroral administration, destined for stimulation of mucosal immunity of infants or sucklings, ~~wherein~~ characterized in that the preparation is infant milk formula or suckling milk formula containing B-cell activating factor.

~~4. The preparation according to claim 2, wherein the preparation is a suspension of B-cell activating factor in water destined for peroral administration.~~

~~5~~3. The preparation according to claim 2, wherein the preparation contains 200 to 3500 pg of B-cell activating factor /ml of the preparation.

~~6~~4. The preparation according to claim ~~5~~3, wherein the preparation contains 400 to 2500 pg of B-cell activating factor /ml of the preparation.

~~7~~5. The preparation according to claim ~~2~~3, wherein the preparation contains 500 ~~or~~ to 2000 pg of B-cell activating factor /ml of the preparation.

6. The use of B-cell activating factor according to claim 1, wherein the medicament contains 200 to 3500 pg of B-cell activating factor/ml.

7. The use of B-cell activating factor according to claim 6, wherein the medicament contains 400 to 2500 pg of B-cell activating factor/ml.

8. The use of B-cell activating factor according to claim 6, wherein the medicament contains 500 to 2000 pg of B-cell activating factor/ml.